An interventional study of Physical activity in Pulmonary Arterial Hypertension, Cardiovascular Diseases and Respiratory Disease, sponsored by University of Nove de Julho. Status unknown at 1 site in Brazil. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-11-04.
Sponsored by University of Nove de Julho · Not applicable, Interventional, and Treatment
Among 48 studies in Pulmonary Arterial Hypertension with a site in Brazil — 12 open to participants now, 15 under way, 5 of them phase 3. Pulmonary Arterial Hypertension · Brazil.
Among the 48 studies in Pulmonary Arterial Hypertension with a site in Brazil, this one is the 36th largest by planned enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2016, is one of 7 with no phase, and was the 19th registered.
699 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →12 of the 48 studies in Pulmonary Arterial Hypertension with a site in Brazil are open now. Recruiting first, the newest first:
University of Sao Paulo General Hospital · Sites in Brazil
Ages 18+
University of Sao Paulo General Hospital · Sites in Brazil
Ages 18+
University of Sao Paulo General Hospital · Sites in Brazil
Ages 18+
University of Sao Paulo General Hospital · Sites in Brazil
Ages 18+
University of Sao Paulo General Hospital · Sites in Brazil
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 20 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 24 · Phase 4 5
First in 2003; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is above the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 215 across the 41 interventional studies, 120 across the 6 observational. Of the 30 that completed or were terminated, 20 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 48 have an industry lead sponsor. The 10 most frequent:
University of Nove de Julho is the lead sponsor of 246 studies on the registry; 52 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 1 (13%) have results posted.
University of Nove de Julho has 2 studies filed under Pulmonary Arterial Hypertension — fewer than ten, so there is no comparison to draw.
7 of the studies in Pulmonary Arterial Hypertension with a site in Brazil that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06274801Phase 3Gossamer Bio USA, Inc.Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) | 2026-12 |
| NCT05649748Phase 3Insmed IncorporatedAn Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) | 2026-12-31 |
| NCT07207525University of Sao Paulo General HospitalInformation Sources in Pulmonary Hypertension | 2026-12 |
| NCT07120789University of Sao Paulo General HospitalValidation of a Patient Knowledge Questionnaire for Pulmonary Hypertension | 2026-12 |
Add all 7 to your calendar (.ics) → With an account.
Among the 48 studies in Pulmonary Arterial Hypertension with a site in Brazil, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Although there has been some progress in pharmacological management of PAH, limited functional capacity and low survival still persist, but there is evidence that exercise training can be accomplished without adverse effects or damage to cardiac function and pulmonary hemodynamics. Specifically, improvements in symptoms, exercise capacity, peripheral muscle function and quality of life. Training programs need to be better studied and well defined, and their physiological effects during physical training and functional capacity.
The aim of this study is to compare the effects of different training exercises on physical performance indicators.
Pulmonary arterial hypertension (PAH) is characterized by pathological changes in the pulmonary vasculature which cause an increase in pulmonary vascular resistance (PVR), restricting the flow of blood through the pulmonary circulation. It is a serious illness, progressive and usually fatal which causes significant functional limitation, mainly due to dyspnea. In order to maintain the flow of blood, pulmonary artery pressure (PAP) increases and the disease progresses leading to right ventricular dysfunction and right heart failure.
Regardless of the cause of PAH, the pulmonary arteries and arterioles have reduced capacity, and increases in cardiac output during exercise is limited. As a result, the delivery of oxygen to peripheral muscles is impaired, contributing to the symptoms of fatigue and dyspnea. While the limitation of the cardiac output to meet peripheral oxygen demand during exercise largely reduces exercise capacity, musculoskeletal dysfunction may also be involved in the exercise limitation in patients with PAH. Changes such as, muscle atrophy, decreased oxidative enzymes and a greater number of type II muscle fibers lead to an early lactic acidosis and decreased functional capacity. A modest evidence exists that exercise training can be done without adverse effects or damage to cardiac and / or pulmonary hemodynamics however, the effectiveness PAH requires more research.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combined Training with 2 types of physical activity
Other: Physical activity
Physical activity with aerobic exercise
Other: Physical activity
Respiratory muscle performance
Other: Physical activity
Effects of different physical activity programs
Functional exercise capacity
Oxygen consumption measurement during cardiopulmonary test
Time frame: Change from Baseline to 15 weeks
6 Minute Walking Test
Distance in meters
Time frame: Change from Baseline to 15 weeks
Incremental shuttle walking test
Distance in meters
Time frame: Change from Baseline to 15 weeks
Autonomic Nervous System
Assesment by Heat Rate Variability analysis
Time frame: Change from Baseline to 15 weeks
Respiratory Muscle Strength
Assesment by Test of Incremental Respiratory Endurance
Time frame: Change from Baseline to 15 weeks
Musculoskeletal Function
Assesment by peripheral muscular strength testing.
Time frame: Change from Baseline to 15 weeks
Change of laboratory parameters, metabolic profile assessment and systemic inflammatory.
IL-1beta, IL-1ra, IL-6, IL-8, IL-10 and TNF-alfa (pg/ml)
Time frame: Change from Baseline to 15 weeks
Exhaled Nitric Oxide
The fraction of eNO (exhaled nitric oxide) in air will be measured by chemiluminescence
Time frame: Change from Baseline to 15 weeks
Lung function (physiological parameter)
Forced vital capacity and liters in 1 second, Total lung capacity, diffusion of carbon dioxide
Time frame: Change from Baseline to 15 weeks
Physical Activity Questionnaire (IPAQ)
The level of physical activity will be assessed using the international questionnaire short-version physical activity (IPAQ). The continuous score allows assessing energy expenditure expressed in MET minutes/week. The IPAQ categorical classifies include: Insufficiently active (does not perform any physical activity); Sufficiently active (conducts vigorous activity at least three days a week \>600 MET - 1400 MET); Very active (performs more than three days per week of vigorous activity 1500 MET - 3000 MET)
Time frame: Change from Baseline to 15 weeks
Endothelial function
Endothelial function will be assessed by flow-mediated dilation (FMD)
Time frame: Change from Baseline to 15 weeks
Plan to share: Undecided
Ran from Jan 2016 to primary completion in Jul 2017, 18 months.
Of 60 non-industry interventional studies with no phase under Pulmonary Arterial Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 63. This study's 18 months is below that.
Counting every sponsor, half of 65 studies reached it within 42 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension →